Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.
- Published In:
- Diabetes, obesity & metabolism (2026)
- Authors:
- Sørensen, Kathrine Kold, Yazdanfard, Puriya Daniel Würtz, Zareini, Bochra, Wood-Kurland, Hannah Karin, Pedersen-Bjergaard, Ulrik, Andersen, Mikkel Porsborg, Michelsen, Jens, Imberg, Henrik, Lind, Marcus, Hallström, Sara, Lanzinger, Stefanie, Munch, Anders, Ohlendorff, Johan Sebastian, Gerds, Thomas Alexander, Torp-Pedersen, Christian
- Database ID:
- RPEP-16204
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16204APA
Sørensen, Kathrine Kold; Yazdanfard, Puriya Daniel Würtz; Zareini, Bochra; Wood-Kurland, Hannah Karin; Pedersen-Bjergaard, Ulrik; Andersen, Mikkel Porsborg; Michelsen, Jens; Imberg, Henrik; Lind, Marcus; Hallström, Sara; Lanzinger, Stefanie; Munch, Anders; Ohlendorff, Johan Sebastian; Gerds, Thomas Alexander; Torp-Pedersen, Christian. (2026). Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70581
MLA
Sørensen, Kathrine Kold, et al. "Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.." Diabetes, 2026. https://doi.org/10.1111/dom.70581
RethinkPeptides
RethinkPeptides Research Database. "Sustained glucagon-like peptide-1 receptor agonist treatment..." RPEP-16204. Retrieved from https://rethinkpeptides.com/research/sorensen-2026-sustained-glucagonlike-peptide1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.